BREA, CALIF., March 31, 2020 — In response to the global COVID-19 pandemic, Beckman Coulter today announced that it is developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2. The assays will be designed for use on any of its high- throughput Access family of immunoassay systems, including the Access 2 and DxI series installed globally.